Global Diabetes Care Devices and Drugs Market

Diabetes Care Devices and Drugs Market Size, Share, Growth Analysis, By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel (Hospital pharmacies, Retail Pharmacies), By End-use (Hospitals, Diagnostic Centers), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35G2119 | Region: Global | Published Date: December, 2025
Pages: 219 | Tables: 62 | Figures: 75

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Diabetes Care Devices and Drugs Market size was valued at USD 32.56 Billion in 2024 and is poised to grow from USD 35.13 Billion in 2025 to USD 64.55 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026–2033).

    Global diabetes care devices and drugs market is highly competitive and fragmented. To maintain a competitive edge, global diabetes care devices major players are working on their market growth by introducing more innovative products that are easy to purchase the consumer and provide more innovative and painless solutions. The intensity of competition among players is high, each player is trying to develop a new device and offer it at a competitive price. Also, to increase their market shares, players are entering new markets, especially in emerging economies where demand is much higher than supply. 'Novo Nordisk (Denmark)', 'Medtronic (Ireland) ', 'Abbott Laboratories (United States) ', 'Johnson & Johnson (United States) ', 'Biocon (India) ', 'Eli Lilly and Company (United States) ', 'Roche (Switzerland) ', 'Bayer (Germany) ', 'Dexcom (United States) ', 'Insulet Corporation (United States) ', 'Tandem Diabetes Care (United States) ', 'Ascensia Diabetes Care (Switzerland) ', 'Terumo Corporation (Japan) ', 'Becton, Dickinson and Company (United States) ', 'AstraZeneca (United Kingdom) ', 'Pfizer (United States) ', 'Merck & Co. (United States) ', 'GlaxoSmithKline (United Kingdom) ', 'McKesson Corporation (United States)'

    The introduction of new products in diabetes monitoring systems and treatment devices is one of the major factors driving the growth of the global diabetes care devices and drugs market. For example, in April 2020, researchers at Portugal's Universidade de Lisboa reported that coating insulin-loaded nanoparticles with chitosan could enhance oral delivery of insulin. Increasing R&D investments and research collaborations may create more opportunities for the further growth of the market.

    Due to the coronavirus (pandemic), global market trend is going to be positive for the market. Individuals diagnosed with diabetes are at a higher risk of contracting the coronavirus and hence demand has increased over the past few years as people look to monitor their diabetes levels. Individuals who were diagnosed with diabetes were looking to avoid hospital visits and stays, and so devices were important for managing illness.

    Based on region, global diabetes care devices and drugs market is sub-segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America dominated the global market in 2022. According to world health organization, In North America, there are more than 29 million diabetic patients and this number is expected to increase to 34 million by 2027. The increase in number of diabetes patients in Europe, lower prices of insulin and insulin delivery devices, increasing demand and sale of insulin delivery devices are the key factors driving the growth of global market.

    Related Reports

    Diabetes Care Devices Market
    Buy Now GET FREE SAMPLE
    Diabetes Device Market
    Buy Now GET FREE SAMPLE
    Insulin Storage Devices Market
    Buy Now GET FREE SAMPLE
    Smart Diabetes Management Market
    Buy Now GET FREE SAMPLE
    Blood Glucose Monitoring Devices Market
    Buy Now GET FREE SAMPLE
    Continuous Glucose Monitoring Devices Market
    Buy Now GET FREE SAMPLE
    Medical Devices Market
    Buy Now GET FREE SAMPLE
    Smart Insulin Pens Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Diabetes Care Devices and Drugs Market

    Report ID: SQMIG35G2119

    $5,300
    BUY NOW GET FREE SAMPLE